Multiple Sclerosis Therapeutics Market, By Drug Class (Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agent, Others), By Route of Administration (Oral, Injection, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharm

Multiple sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system (CNS). It is caused when the immune system attacks myelin, the protective sheath surrounding nerve fibers of the CNS. The damage disrupts communication between the brain and other parts of the body. Symptoms can be mild or severe, depending on the number and location of lesions in the CNS. Common symptoms include fatigue, weakness or numbness in the limbs, poor coordination and balance, vision problems, and cognitive dysfunction. There has been no known cure for MS but medications such as interferons, glatiramer acetate, monoclonal antibodies, corticosteroids can manage the disease symptoms and slow down its progression.

Market Dynamics:

Global multiple sclerosis therapeutics market growth is driven by factors like increasing prevalence of multiple sclerosis across both developed and developing nations, growing geriatric population, robust pipeline of new and innovative treatment therapies for multiple sclerosis, surging healthcare spending, and availability of reimbursement schemes. However, high costs associated with multiple sclerosis drugs can hamper the market growth. Emergence of personalized medicines for multiple sclerosis treatment, growing adoption of combination therapies, infusion therapies, and oral drugs for multiple sclerosis treatment can offer market growth opportunities.

Key features of the study:

• This report provides in-depth analysis of the global multiple sclerosis therapeutics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global multiple sclerosis therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Biogen, Novartis, Merck, Sanofi, Teva Pharmaceuticals, Bayer, ACORDA THERAPEUTICS and CELGENE
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global multiple sclerosis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global multiple sclerosis therapeutics market

• By Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
• Beta Interferon
• Corticosteroids
• Monoclonal Antibodies
• Antineoplastic Agent
• Others
• By Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
• Oral
• Injection
• Others
• By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Regional Insights (Revenue, USD Bn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Biogen Inc.
• Novartis AG
• Merck KGaA
• Sanofi S. A.
• Acorda Therapeutics, Inc.
• Teva Pharmaceuticals Industries Ltd.
• Bristol-Myers Squibb Company
• Bayer AG
• Hoffmann-La Roche AG
• Viatris Inc. (Mylan NV)
• Johnson & Johnson
• EMD Serono, Inc.
• TG Therapeutics, Inc.
• Genentech, Inc.
• Celgene Corporation
• AbbVie Inc.
• Amgen Inc.
• UCB S.A.
• Sandoz (a Novartis division)
• Ipsen S.A.